Simulations Plus Stock

Simulations Plus EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Simulations Plus (SLP) as of Jul 26, 2026 is -3.50. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 40.39 — a change of -108.67% (lower).

EV/EBIT

-3.50

YoY

-108.67%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Simulations Plus is 2026 -3.50 . EV/EBIT (Enterprise Value to EBIT) of Simulations Plus was 2025 40.39 . It decreases by -108.67% lower compared to the previous year.

The Simulations Plus EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
49.98 base
Jan 1, 2020
128.90 base
Jan 1, 2021
87.20 base
Jan 1, 2022
51.07 base
Jan 1, 2023
104.01 base
Jan 1, 2024
92.19 base
Jan 1, 2025
-5.21 base
Jan 1, 2026 (e)
15.74 base
YEARPRICE-TO-EBIT
2026 est 15.74
2025 -5.21
2024 92.19
2023 104.01
2022 51.07
2021 87.20
2020 128.90
2019 49.98
2018 34.78
2017 34.79
2016 23.23
2015 29.20
2014 25.73
2013 20.30
2012 19.89
2011 13.66
2010 15.49
2009 12.78
2008 7.40
2007 28.13
2006 59.51
Access this data via the Eulerpool API
Get Free API Key

Simulations Plus Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Simulations Plus's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Simulations Plus's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Simulations Plus's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Simulations Plus grows earnings faster than its peers.

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

EV/EBIT (Enterprise Value to EBIT) of Simulations Plus is -3.50 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Simulations Plus

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Simulations Plus